Get the Stockscreener App
0.4321
0.14%
-0.0006
Akili Inc stock is currently priced at $0.4321, with a 24-hour trading volume of 102.49K.
It has seen a -0.14% decreased in the last 24 hours and a +92.22% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4309 pivot point. If it approaches the $0.4418 resistance level, significant changes may occur.
Previous Close:
$0.4327
Open:
$0.4327
24h Volume:
102.49K
Market Cap:
$33.96M
Revenue:
$1.68M
Net Income/Loss:
$-59.49M
P/E Ratio:
3.4707
EPS:
0.1245
Net Cash Flow:
$-58.01M
1W Performance:
-2.77%
1M Performance:
+92.22%
6M Performance:
-5.26%
1Y Performance:
-69.57%
1D Range:
$0.421
$0.44
52W Range:
$0.1912
$1.67
Akili Inc Stock (AKLI) Company Profile
Name
Akili Inc
Sector
Industry
Phone
617 456 0597
Address
125 Broad Street, 5th Floor, Boston
Akili Inc Stock (AKLI) Latest News
Akili Reports First Quarter 2024 Financial Results and Provides Business Update - Business Wire
Business Wire
Akili (NASDAQ:AKLI) Stock Price Down 0.5% - Defense World
Defense World
Akili, Inc. (NASDAQ:AKLI) Short Interest Update - Defense World
Defense World
Therapeutic video game maker Akili lays off workers for third time in 16 months - The Business Journals
The Business Journals
Akili layoffs hit 46% of employees - Modern Healthcare
Modern Healthcare
Analyzing the Impact of Earnings Reports on Akili Inc Inc. (AKLI) Price Performance – Invest Chronicle - The InvestChronicle
The InvestChronicle
Akili Inc Stock (AKLI) Financials Data
Akili Inc (AKLI) Revenue 2024
AKLI reported a revenue (TTM) of $1.68 million for the quarter ending December 31, 2023, a +419.50% rise year-over-year.
Akili Inc (AKLI) Net Income 2024
AKLI net income (TTM) was -$59.49 million for the quarter ending December 31, 2023, a -647.02% decrease year-over-year.
Akili Inc (AKLI) Cash Flow 2024
AKLI recorded a free cash flow (TTM) of -$58.01 million for the quarter ending December 31, 2023, a +30.58% increase year-over-year.
Akili Inc (AKLI) Earnings per Share 2024
AKLI earnings per share (TTM) was -$0.7623 for the quarter ending December 31, 2023, a -456.42% decline year-over-year.
Akili Inc Stock (AKLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Martucci Walter Edward II | Chief Executive Officer |
Sep 11 '23 |
Sale |
1.05 |
2,353 |
2,471 |
3,150,180 |
| Franklin Matthew | President & COO |
Sep 11 '23 |
Sale |
1.05 |
1,728 |
1,814 |
753,898 |
| Studer Jacqueline | Chief Legal Officer |
Sep 11 '23 |
Sale |
1.05 |
1,130 |
1,186 |
348,292 |
| Shanbhag Santosh | Chief Financial Officer |
Sep 11 '23 |
Sale |
1.05 |
830 |
872 |
323,636 |
About Akili Inc
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive dysfunction. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine design to target neutral system, such as focus, interference processing, and multitasking; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company is headquartered in Boston, Massachusetts.
3.45%
1.02%
Cap:
|
Volume (24h):